tailieunhanh - MiR-762 activation confers acquired resistance to gefitinib in non-small cell lung cancer

Epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) (. gefitinib) currently remain the first-line treatment for patients with advanced non-small-cell lung cancer (NSCLC) with activating EGFR mutation. | MiR-762 activation confers acquired resistance to gefitinib in non-small cell lung cancer

TÀI LIỆU LIÊN QUAN
TỪ KHÓA LIÊN QUAN
TÀI LIỆU MỚI ĐĂNG
54    139    1    23-11-2024
14    141    0    23-11-2024